Company Is also Seeking Shareholder Approval of Amended and Restated Omnibus PlanTORONTO and HAIFA, Israel, June 04, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”) is pleased to announce that on May 22, 2025, it presented new manufacturing process data at the 4th annual meeting of the Israeli Society for Extracellular Vesicles Research (“ISEVR”), a conference dedicated to cutting-edge exosome science. Additionally, the Company will seek sh ...

DELAWARE, Ohio, June 04, 2025 (GLOBE NEWSWIRE) -- Greif, Inc. (NYSE: GEF, GEF.B), a global leader in industrial packaging products and services, today announced fiscal second quarter 2025 results. Fiscal Second Quarter 2025 Financial Highlights: (all results compared to the second quarter of 2024 unless otherwise noted) Net income increased 6.5% to $47.3 million or $0.82 per diluted Class A share compared to net income of $44.4 million or $0.77 per diluted Class A share. Net income, excluding the impact of ...

Core Insights - Cullinan Therapeutics has advanced its leadership in T cell engager (TCE) development for autoimmune diseases, with both a CD19 TCE and BCMA TCE in its pipeline [1] - The company has strengthened its portfolio of autoimmune programs, aiming to address a broader range of diseases while ensuring cash runway into 2028 [1][5] - Cullinan has entered into an agreement with Genrix Bio for an exclusive global license to velinotamig, a BCMAxCD3 bispecific T cell engager, which has shown promising efficacy in treating relapsed/refractory multiple myeloma [2][3] Company Developments - Velinotamig has demonstrated potential best-in-class efficacy at the Phase 2 target dose in nearly 50 patients with relapsed/refractory multiple myeloma [2] - The agreement includes an upfront license fee of $20 million, with potential future payments of up to $292 million in development and regulatory milestones, plus up to $400 million in sales-based milestones [4] - Cullinan plans to leverage data from Genrix's Phase 1 study in China to accelerate global clinical development of velinotamig in autoimmune diseases [3][4] Industry Context - T cell engagers are viewed as the next wave of innovation in autoimmune diseases, with BCMA as a promising target for a precise and potentially disease-modifying approach [3] - The collaboration with Genrix Bio is expected to enhance Cullinan's capabilities in developing therapies for autoimmune diseases, addressing the needs of a wider patient population [4][10]

GAITHERSBURG, Md., June 04, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today announced the appointment of George Scorsis as the Chairman of the Board of Directors. Mr. Scorsis has served as director of the Company since February 2025. Mr. Scorsis has over 25 years of experience leadin ...

See-Mode’s commercially available AI-powered ultrasound detection, characterization, and reporting solutions for thyroid and breast will be integrated into RadNet’s DeepHealth population health solutionsReal-world deployment of See-Mode’s FDA-approved thyroid ultrasound solution at RadNet imaging centers demonstrates improved workflow efficiency and enhanced diagnostic accuracy The acquisition positions RadNet at the forefront of AI innovation in ultrasound LOS ANGELES, June 04, 2025 (GLOBE NEWSWIRE) -- Rad ...

NEWARK, N.J., June 04, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL; NYSE American: RFL-WT) announced today the final results and closing of its $25.0 million rights offering (the “Rights Offering”). The subscription period of the Rights Offering expired at 5:00 P.M. Eastern Time, on May 29, 2025. The Rights Offering resulted in subscriptions for 3,130,480 shares of Class B common stock at an exercise price of $1.28 per share for aggregate gross proceeds of $4,007,014.40.The subscriptions do no ...

Core Insights - Five Below, Inc. reported a 19.5% increase in net sales to $970.5 million for Q1 2025, with comparable sales rising by 7.1% [1][8] - The company announced a GAAP diluted EPS of $0.75 and an adjusted diluted EPS of $0.86 for the same quarter [1][8] - Five Below raised its full-year 2025 sales guidance and increased the low end of its EPS guidance range [1][8] - A transition in the CFO position was announced, with the COO taking on the interim role [5][6] Financial Performance - Net sales for Q1 2025 were $970.5 million, up from $811.9 million in Q1 2024 [8] - Operating income increased to $50.8 million from $36.2 million year-over-year [8] - Adjusted operating income rose to $59.6 million compared to $38.1 million in Q1 2024 [8] - Net income for the quarter was $41.1 million, up from $31.5 million in the prior year [8] - Adjusted net income was $47.5 million, compared to $33.0 million in Q1 2024 [8] Store Expansion - Five Below opened 55 new stores, bringing the total to 1,826 stores across 44 states, representing a 13.8% increase in store count from the previous year [8] Guidance and Outlook - For Q2 2025, the company expects net sales between $975 million and $995 million, with comparable sales projected to increase by 7% to 9% [12] - Full-year 2025 net sales are anticipated to be in the range of $4.33 billion to $4.42 billion, with a comparable sales increase of 3% to 5% [12]

TORONTO and TAMPA, Fla., June 04, 2025 (GLOBE NEWSWIRE) -- Voxtur Analytics Corp. (TSXV: VXTR; OTCQB: VXTRF) ("Voxtur" or the "Company"), a North American technology company creating a more transparent and accessible real estate lending ecosystem, today issued a letter from Ryan Marshall, the Company’s CEO. “Over the past year, Voxtur has undergone profound transformation in the face of relentless challenges both internal and external. While our most recent financial statements contain disclosures that may ...

TORONTO, June 04, 2025 (GLOBE NEWSWIRE) -- Currency Exchange International, Corp. (the “Company”) (TSX: CXI; OTCQX: CURN), will report its financial results for the Second Quarter of 2025 (ended April 30, 2025) after-market close on Wednesday, June 11, 2025. Following the release, Currency Exchange International Corp. will host an earnings conference call with management on Thursday, June 12, 2025 at 8:30 a.m. EST, in which they will discuss these recent financial and operational results. CXI Second Quarter ...

ORLANDO, Fla., June 04, 2025 (GLOBE NEWSWIRE) -- Abacus Global Management, Inc. (“Abacus” or the “Company”) (NASDAQ: ABL), a leader in the alternative asset management space, today provided the following response to a false and misleading short attack. Abacus has been buying and selling life insurance policies for over two decades with long-standing and trusted counter-party relationships. If Abacus used flawed data causing over-valuation of the underlying insurance product assets, the Company would be goin ...